GLP-1 medications reduce appetite and slow down digestion. Svitlana Pietukhova/Getty Images

Winning is all about losing when it comes to weight-loss drugs. Eli Lilly thinks it has a REAL loser on its hands.

The pharma giant published results from its first clinical trial pitting retatrutide, a next-generation injectable medication awaiting regulatory approval, against Ozempic.

Patients with type 2 diabetes using retatrutide, or "reta" as some know it, lost, on average, more than twice as much weight (47 pounds) as those on the highest dose of Ozempic (21 pounds) during 16 months.

BI's Hilary Brueck has all the details on the trial here .

Dubbed "King Kong" or " triple G " because it mimics three different hormones, some believe the weight loss that users experience using reta could rival bariatric surgery.

Some of you might be well aware of reta. Even though it's still in clinical trials, copycat peptide sellers have flooded the gray market with knock-off versions.…